Cullinan Therapeutics (CGEM) Return on Sales (2021)
Cullinan Therapeutics' (CGEM) quarterly Return on Sales came in at 0.04% in Q4 2021, down 4855.81% quarter-over-quarter from 0.0% in Q1 2021.
Cullinan Therapeutics (CGEM) Return on Sales (2021) Analysis & Trends
Cullinan Therapeutics' Return on Sales history runs 1 years deep, the most recent figure standing at 0.04% for Q4 2021.
- On a quarterly basis, Return on Sales changed N/A year-over-year to 0.04% in Q4 2021; TTM through Dec 2021 was 0.04%, a N/A change from a year earlier, with the FY2021 full-year figure at 0.04%, changed N/A from the prior year.
- Return on Sales eased to 0.04% in Q4 2021 per CGEM's latest filing, from 0.0% in the prior quarter.
- Across five years, Return on Sales topped out at 0.0% in Q1 2021 and bottomed at 0.04% in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.00% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.00% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.00% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 0.00% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cullinan Therapeutics | 368.65 Mn | 368.65 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -0.04% |
| Mar 31, 2021 | 0.00% |